July 8, 2024 - 🧬 [nGram] Today’s Oncology Scoop: Immorna, IDEAYA, Hinova, Biostar, iTeos, Myricx, XPOVIO, Olverembatinib, IASO

  1. Immorna Biotherapeutics receives U.S. FDA IND clearance to conduct Phase 1/2 study of JCXH-211 IV
    • Immorna Biotherapeutics received FDA IND clearance for JCXH-211 IV, a self-replicating mRNA encoding IL-12 protein.
    • The Phase 1/2 study will be multi-center, open-label, and will assess safety, tolerability, and preliminary efficacy.
    • The study aims to determine the recommended Phase 2 dose (RP2D) for JCXH-211 IV in combination with a checkpoint inhibitor.
    • JCXH-211 IV has shown superior tumor-eradicating potency in preclinical models and excellent safety in nonclinical studies.
    Read more

  2. IDEAYA announces positive interim phase 2 monotherapy expansion data for IDE397 in MTAP-deletion urothelial and lung cancer
    • IDE397 showed a 39% overall response rate (ORR) with 1 complete response (CR) and 6 partial responses (PRs) in 18 evaluable patients.
    • The disease control rate (DCR) was 94%, with 1 CR, 6 PRs, and 10 stable diseases (SD).
    • 78% of patients experienced tumor shrinkage, and 81% had a ctDNA molecular response rate (MRR) with >50% ctDNA reduction.
    • The adverse event profile was favorable, with only 5.6% grade 3 or higher drug-related AEs and no drug-related serious adverse events (SAEs).
    Read more

  3. Hinova Pharmaceuticals receives FDA Fast Track designation for HP518 for treatment of AR+ triple-negative breast cancer
    • Hinova Pharmaceuticals has been granted FDA Fast Track designation for HP518, an investigational drug for AR+ triple-negative breast cancer (TNBC).
    • HP518 is a potent PROTAC AR degrader showing efficacy in AR+ TNBC, with promising antitumor activity and a favorable safety profile in preclinical studies.
    • The Fast Track designation aims to expedite the development and review process for drugs addressing serious conditions and unmet medical needs.
    • Hinova plans to update the existing IND for TNBC development and is committed to accelerating HP518's development.
    Read more

  4. Biostar Pharma announces FDA clearance of the IND application for a phase 2 study of utidelone injection (UTD1) in HER2- breast cancer brain metastasis
    • Biostar Pharma received FDA clearance for a phase 2 study of Utidelone Injection (UTD1) in HER2- breast cancer brain metastasis (BCBM).
    • The study, BG01-2402, will evaluate the efficacy of Utidelone Injection combined with capecitabine in HER2- BCBM patients.
    • The trial will be conducted at 10-15 sites in the US, targeting the enrollment of 120 patients.
    • Primary endpoint is CNS-ORR; secondary endpoints include PFS, DOR, and OS.
    Read more

  5. iTeos announces first patient dosed in GALAXIES Lung-301 phase 3 study, earning $35 million in milestones from GSK
    • iTeos has dosed the first patient in the GALAXIES Lung-301 Phase 3 trial for belrestotug + dostarlimab.
    • The trial is a global, randomized, double-blind study comparing belrestotug + dostarlimab to placebo + pembrolizumab in advanced, unresectable, or metastatic PD-L1 high NSCLC.
    • This milestone triggers $35 million in development payments from GSK.
    • iTeos and GSK's collaboration includes a $625 million upfront payment, with potential additional milestones and profit-sharing agreements.
    Read more

  6. Bio-Path Holdings provides clinical update and expansion plans
    • Bio-Path Holdings is advancing its DNAbilize platform with significant progress in clinical trials for multiple cancer indications.
    • The company has developed a molecular biomarker package to enhance the success of prexigebersen treatment in oncology studies.
    • A Phase 2 clinical trial for prexigebersen in Acute Myeloid Leukemia (AML) is ongoing, with plans to complete enrollment in the next 18 months.
    • Bio-Path is preparing for preclinical studies to evaluate prexigebersen as a potential treatment for obesity, leveraging existing safety data from leukemia patients.
    Read more

  7. Myricx Bio announces £90m ($114m) series A financing to advance its novel NMTi-ADC therapeutics into clinical development
    • Myricx Bio raised £90m ($114m) in series A financing co-led by Novo Holdings and Abingworth.
    • Funds will be used to develop Myricx's N-Myristoyltransferase inhibitor (NMTi) ADC payload platform and advance its pipeline.
    • New investors include British Patient Capital, Cancer Research Horizons, and Eli Lilly, alongside founding investors Brandon Capital and Sofinnova Partners.
    • Myricx plans to establish laboratory operations in London and expand its management and R&D teams.
    Read more

  8. Xpovio approved for new indication in DLBCL in China
    • Xpovio (selinexor) approved as monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) in China.
    • Approval supported by the SEARCH study, which showed a significant overall response rate among 60 Chinese patients.
    • Xpovio is an oral drug with a novel mechanism of action, currently being developed for multiple indications.
    • Antengene has submitted NDAs for Xpovio in other ASEAN markets, with approvals anticipated in the second half of 2024.
    Read more

  9. Olverembatinib approved for commercialization in Macau China
    • Ascentage Pharma's olverembatinib has been approved by the Pharmaceutical Administration Bureau (ISAF) of Macau SAR for treating TKI-resistant CML-CP and CML-AP.
    • Olverembatinib is the first third-generation BCR-ABL1 inhibitor approved by China's NMPA and targets BCR-ABL1 mutants, including the T315I mutation.
    • The drug is being jointly commercialized in China by Ascentage Pharma and Innovent Biologics.
    • Olverembatinib has received multiple designations, including Priority Review and Breakthrough Therapy by China's NMPA, and Orphan Drug and Fast Track by the US FDA.
    Read more

  10. IASO Bio and Innovent enhance strategic collaboration in cell therapy
    • IASO Bio and Innovent have agreed on a new strategic collaboration involving FUCASO® (Equecabtagene Autoleucel).
    • IASO Bio will purchase Innovent's rights to FUCASO® and obtain a global commercial license for the product.
    • Innovent will acquire an 18% stake in IASO Bio as part of the agreement.
    • FUCASO® is approved by the NMPA for treating relapsed/refractory multiple myeloma and has IND applications for other indications.
    Read more